



Long COVID from rheumatology perspective: a simple mimicker or promoter of autoimmunity?

Alexandros A. Drosos¹ · Eleftherios Pelechas¹ · Paraskevi V. Voulgari¹

Received: 31 January 2022 / Revised: 31 January 2022 / Accepted: 2 February 2022 / Published online: 11 February 2022
© International League of Associations for Rheumatology (ILAR) 2022

Dear editor,

We have read with great interest the review article by Sapkota et al. which has been recently published in the *Clinical Rheumatology* journal dealing with long COVID [1]. In this paper, the authors reported the symptoms and immunological findings of patients who were infected from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). These symptoms and laboratory features share similarities with those of patients suffering from autoimmune rheumatic diseases (ARDs). They concluded that long COVID is a mimicker of ARDs and needs to be excluded to ensure a correct diagnosis [1].

Recently, we reported a patient who contracted SARS-CoV-2 infection and developed an erosive seronegative arthritis six months after infection [2]. Musculoskeletal, cutaneous, and other systemic manifestations, along with the presence of autoantibodies, are frequently observed in these patients. On the other hand, SARS-CoV-2 may trigger autoimmune responses and the development of de novo manifestations of ARDs, as in our patient [3]. The pathogenesis of these phenomena is not well defined. One hypothesis implies the presence of autoantibodies against interferon (IFN) type-I, or inborn errors in the type-I IFN immunity [4, 5]. Another hypothesis is that SARS-CoV-2

might trigger autoimmune responses through molecular mimicry [3]. Several viruses have been implicated as possible etiological factors for the development of ARDs, mostly systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and others. Between viruses Epstein-Barr virus (EBV) is implicated in the pathogenesis of the above disorders [3, 6]. Indeed, EBV can trigger immune responses through molecular mimicry and is a polyclonal activator of B-cells and increases the production of rheumatoid factor (RF). Several studies suggested that molecular mimicry is a possible mechanism responsible for the development of ARDs in SARS-CoV-2 infection [7, 8]. Thus, SARS-CoV-2 may trigger autoimmunity and the possible development of the de novo manifestations of ARDs.

Declarations

Disclosures None.

References

1. Sapkota HR, Nune A (2022) Long COVID from rheumatology perspective - a narrative review. *Clin Rheumatol* 41:337–348
2. Drosos AA, Pelechas E, Voulgari PV (2021) Seronegative Erosive Arthritis Following SARS-CoV-2 Infection. *Rheumatol Ther* 16:1–7. <https://doi.org/10.1007/s40744-021-00395-9>
3. Ramos-Casals M, Brito-Zerón P, Mariette X (2021) Systemic and organ-specific immune-related manifestations of COVID-19. *Nat Rev Rheumatol* 17:315–332
4. Bastard P, Rosen LB, Zhang Q et al (2020) Autoantibodies against type I IFNs in patients with life-threatening COVID-19. *Science* 370:eabd4585
5. Zhang Q, Bastard P, Liu Z et al (2020) Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. *Science* 370:eabd4570
6. Jog NR, Young KA, Munroe ME et al (2019) Association of Epstein-Barr virus serological reactivation with transitioning to

This comment refers to the article available online at <https://doi.org/10.1007/s10067-021-06001-1>.

✉ Alexandros A. Drosos
adrosos@uoi.gr
<https://www.rheumatology.gr>
Eleftherios Pelechas
pelechas@doctors.org.uk
Paraskevi V. Voulgari
pvoulgar@uoi.gr

¹ Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece

- systemic lupus erythematosus in at risk-individuals. *Ann Rheum Dis* 78:1235–1241
7. Marino Gammazza A, Légaré S, Lo Bosco G et al (2020) Human molecular chaperons share with SARS-CoV-2 antigenic epitopes potentially capable of eliciting autoimmunity against endothelial cells: possible role of molecular mimicry in COVID-19. *Cell Stress Chaperons* 25:737–741
 8. Lucchese G, Flöel A (2020) Molecular mimicry between SARS-CoV-2 and respiratory pacemaker neurons. *Autoimmun Rev* 19:102556. <https://doi.org/10.1016/j.autrev.2020.102556>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.